Evidence map›Paper›PMID 34834541›Full record

ArticleJournal of personalized medicine2021

Long Term Metabolic and Inflammatory Effects of Second-Generation Antipsychotics: A Study in Mentally Disordered Offenders.

Emilia Vassilopoulou, Dimitris Efthymiou, Evangelia Papatriantafyllou, Maria Markopoulou, Efthymia-Maria Sakellariou, Alina Codruta Popescu

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Emilia VassilopoulouDepartment of Nutritional Sciences and Dietetics, International Hellenic University, 57400 Thessaloniki, Greece.ORCID 0000-0002-2665-5908
Dimitris EfthymiouDepartment of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Evangelia PapatriantafyllouDepartment of Nutritional Sciences and Dietetics, International Hellenic University, 57400 Thessaloniki, Greece.
Maria MarkopoulouDepartment of Forensic Psychiatry, Psychiatric Hospital of Thessaloniki, 56429 Thessaloniki, Greece.
Efthymia-Maria SakellariouPsychiatric Clinic, General University Hospital, 41110 Larissa, Greece.
Alina Codruta PopescuDepartment of Abilities Human Sciences, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.ORCID 0000-0002-3691-8871
International Hellenic University · GRAristotle University of Thessaloniki · GRIuliu Hațieganu University of Medicine and Pharmacy · ROUniversity Hospital of Larissa · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mentally disordered offenders provided with forensic psychiatric care are often treated with second generation antipsychotic (SGA) medication and experience metabolic and inflammatory side effects.

aimIn this paper, we monitored the three-year fluctuation of selected anthropometric, biochemical, and inflammatory indices in forensic psychiatric patients receiving antipsychotic (AP) medication for more than five years, according to the type of AP.

methodsThirty-five patients with psychotic disorders were classified into two groups based on the type of AP. Specifically: AP1, related to a lower risk, and AP2, related to an increased risk of weight gain (WG) and metabolic complications. Biochemical, hematological, anthropometric, blood pressure (BP), and medication data were retrieved from the individual medical files. Statistical analysis was performed with SPSS 23.

resultsNo significant differences in weight and glucose and cholesterol levels were observed, but patients taking AP2 more often needed drugs to control diabetes mellitus (DM), lipidemia, and cardiovascular disease (CVD). In those taking AP1, the mean HDL level decreased significantly over time (

conclusionsThe proposed sub-classification of SGAs into AP1 and AP2, depending on their potential for metabolic and inflammatory effects, might facilitate study of their long-term side-effects but also help in personalized prevention or treatment measures to counteract these side-effects.

Indexed as

antipsychotic drugsforensic psychiatrymetabolic disturbances

Identifiers

PMID34834541
PMCPMC8617708
OpenAlexW3211772857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.